

FORBIUS

Forbius Nominated for “Best New Drug Developer” Award for the 2018 World ADC Awards

(October 11, 2018) – Forbius (Formation Biologics) announces today that it was nominated in the “Best New Drug Developer” category for the [5th Annual World ADC Awards](#). This competitive nomination process involved over 2,545 casted votes to recognize leaders and innovators in the antibody-drug conjugate (ADC) research field.

Forbius' lead program, AVID100, is an ADC targeting EGFR. AVID100 is undergoing Phase 2 clinical trials in patients with confirmed EGFR overexpression in squamous cell carcinoma of the head and neck, squamous non-small cell lung cancer, and triple negative breast cancer. Phase 2a development of AVID100 is supported by the recently announced [\\$18.75M peer-reviewed grant from the Cancer Prevention Research Institute of Texas \(CPRIT\)](#).

About Forbius (Formation Biologics)

Forbius is a clinical stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. Forbius' medicines are designed to radically transform patients' lives. We use our strength in biological understanding and diverse protein engineering technologies to design superior inhibitors of validated pathways. We have particularly deep expertise in targeting the transforming growth factor-beta (TGF- β) and epidermal growth factor receptor (EGFR) pathways. For both of these pathways, there is a significant body of evidence validating their role as drivers of multiple life-threatening conditions, including cancer and fibrosis. However, in the case of the EGFR pathway, the majority of patients do not benefit from currently marketed EGFR inhibitors; in the case of the TGF- β pathway, no agent targeting this pathway has yet been approved. By using multiple complementary platform technologies, Forbius' team overcame barriers that prevented the development of effective therapeutics targeting these pathways. For more information, please visit www.forbius.com.